SRNE logo

Sorrento Therapeutics (SRNE) CAPEX

Annual CAPEX

$13.66 M
+$4.79 M+53.95%

December 31, 2022

Summary

Performance

1-Year Change

+53.95%

3-Year Change

+19.36%

5-Year Change

+24.47%

15-Year Change

+24.47%

SRNE CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

70.14%
SRNE annual capital expenditures is higher than 70.14% of companies in Healthcare sector

High & Low

All-time High

$13.66 M
SRNE annual capital expenditures is currently at an all-time high

3-Year Low

$8.87 M
SRNE annual capital expenditures is currently +53.95% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
SRNE previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

May 15, 2025
SRNE next annual earnings announcement is scheduled for May 15, 2025

OtherSRNEcash flowmetrics:

Annual FCF

-$307.51 M
SRNE annual free cash flow is -$307.51 million

Annual CFO

-$293.86 M
SRNE annual cash flow from operations is -$293.86 million

Annual CFI

-$28.52 M
SRNE annual cash flow from investing activities is -$28.52 million

Annual CFF

$311.72 M
SRNE annual cash flow from financing activities is $311.72 million

Quarterly CAPEX

$140.00 K
+$54.00 K+62.79%

June 30, 2023

Summary

Performance

3-Month Change

+62.79%

1-Year Change

+62.79%

3-Year Change

+62.79%

5-Year Change

+62.79%

SRNE Quarterly CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

33.58%
SRNE quarterly capital expenditures is higher than 33.58% of companies in Healthcare sector

High & Low

All-time High

$25.20 M
SRNE quarterly capital expenditures is currently -99.44% below its historical high of $25.20 million

3-Year Low

$86.00 K
SRNE quarterly capital expenditures is currently +62.79% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2023
SRNE previous earnings announcement was published on Jun 30, 2023

Next Quarterly Earnings Report Date

May 15, 2025
SRNE next earnings announcement is scheduled for May 15, 2025

OtherSRNEcash flowmetrics:

Quarterly FCF

-$55.80 M
SRNE quarterly free cash flow is -$55.80 million

Quarterly CFO

-$55.66 M
SRNE quarterly cash flow from operations is -$55.66 million

Quarterly CFI

-$140.00 K
SRNE quarterly cash flow from investing activities is -$140.00 thousand

Quarterly CFF

$88.81 M
SRNE quarterly cash flow from financing activities is $88.81 million

TTM CAPEX

$8.59 M
-$2.56 M-23.00%

June 30, 2023

Summary

Performance

3-Month Change

-23%

1-Year Change

-23%

3-Year Change

-23%

5-Year Change

-23%

SRNE TTM CAPEX Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

61.73%
SRNE TTM capital expenditures is higher than 61.73% of companies in Healthcare sector

High & Low

All-time High

$28.02 M
SRNE TTM capital expenditures is currently -69.37% below its historical high of $28.02 million

3-Year Low

$8.59 M
SRNE TTM capital expenditures is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2023
SRNE previous earnings announcement was published on Jun 30, 2023

Next Quarterly Earnings Report Date

May 15, 2025
SRNE next earnings announcement is scheduled for May 15, 2025

OtherSRNEcash flowmetrics:

TTM FCF

-$243.21 M
SRNE TTM free cash flow is -$243.21 million

TTM CFO

-$234.63 M
SRNE TTM cash flow from operations is -$234.63 million

TTM CFI

-$11.58 M
SRNE TTM cash flow from investing activities is -$11.58 million

TTM CFF

$246.59 M
SRNE TTM cash flow from financing activities is $246.59 million

SRNE CAPEX Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+54.0%+62.8%-23.0%
3 y3 years+19.4%+62.8%-23.0%
5 y5 years+24.5%+62.8%-23.0%

SRNE CAPEX Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+54.0%-96.9%+62.8%-37.1%at low
5 y5-yearat high+109.2%-99.4%+100.7%-69.4%+166.2%
alltimeall timeat high>+9999.0%-99.4%+100.7%-69.4%+166.2%

Sorrento Therapeutics CAPEX History

DateAnnualQuarterlyTTM
Jun 2023
-
$140.00 K(+62.8%)
$8.59 M(-23.0%)
Mar 2023
-
$86.00 K(-98.1%)
$11.15 M(-18.4%)
Dec 2022
$13.66 M(+54.0%)
$4.52 M(+18.0%)
$13.66 M(+20.4%)
Sep 2022
-
$3.83 M(+41.8%)
$11.34 M(+30.6%)
Jun 2022
-
$2.71 M(+4.3%)
$8.68 M(-8.3%)
Mar 2022
-
$2.59 M(+17.4%)
$9.47 M(+6.8%)
Dec 2021
$8.87 M(+35.9%)
$2.21 M(+88.0%)
$8.87 M(-168.4%)
Sep 2021
-
$1.18 M(-66.4%)
-$12.97 M(-217.5%)
Jun 2021
-
$3.49 M(+75.2%)
$11.04 M(+29.9%)
Mar 2021
-
$1.99 M(-110.2%)
$8.50 M(+30.2%)
Dec 2020
$6.53 M(-42.9%)
-$19.64 M(-177.9%)
$6.53 M(-76.7%)
Sep 2020
-
$25.20 M(+2554.9%)
$28.02 M(+469.2%)
Jun 2020
-
$949.00 K(+4419.0%)
$4.92 M(-21.0%)
Mar 2020
-
$21.00 K(-98.9%)
$6.24 M(-45.5%)
Dec 2019
$11.44 M(+2.2%)
$1.86 M(-11.2%)
$11.44 M(-23.9%)
Sep 2019
-
$2.09 M(-7.3%)
$15.03 M(-5.3%)
Jun 2019
-
$2.26 M(-56.8%)
$15.87 M(-0.7%)
Mar 2019
-
$5.23 M(-4.0%)
$15.97 M(+42.7%)
Dec 2018
$11.20 M(+2.0%)
$5.45 M(+85.5%)
$11.20 M(+52.3%)
Sep 2018
-
$2.94 M(+24.2%)
$7.35 M(+5.0%)
Jun 2018
-
$2.36 M(+427.7%)
$7.00 M(-3.6%)
Mar 2018
-
$448.00 K(-72.0%)
$7.26 M(-33.8%)
Dec 2017
$10.97 M(+59.9%)
$1.60 M(-38.1%)
$10.97 M(-12.5%)
Sep 2017
-
$2.59 M(-1.3%)
$12.54 M(+9.9%)
Jun 2017
-
$2.62 M(-37.0%)
$11.41 M(+9.5%)
Mar 2017
-
$4.16 M(+31.2%)
$10.43 M(+52.0%)
DateAnnualQuarterlyTTM
Dec 2016
$6.86 M(+85.1%)
$3.17 M(+117.6%)
$6.86 M(+26.0%)
Sep 2016
-
$1.46 M(-10.8%)
$5.45 M(+0.1%)
Jun 2016
-
$1.63 M(+174.2%)
$5.44 M(+37.3%)
Mar 2016
-
$596.00 K(-66.1%)
$3.96 M(+6.8%)
Dec 2015
$3.71 M(+527.2%)
$1.76 M(+21.2%)
$3.71 M(+75.9%)
Sep 2015
-
$1.45 M(+823.6%)
$2.11 M(+136.1%)
Jun 2015
-
$157.00 K(-54.2%)
$893.00 K(+6.3%)
Mar 2015
-
$343.00 K(+117.1%)
$840.00 K(+42.1%)
Dec 2014
$591.00 K(-36.5%)
$158.00 K(-32.8%)
$591.00 K(+19.6%)
Sep 2014
-
$235.00 K(+126.0%)
$494.00 K(-45.2%)
Jun 2014
-
$104.00 K(+10.6%)
$901.00 K(+10.1%)
Mar 2014
-
$94.00 K(+54.1%)
$818.00 K(-12.1%)
Dec 2013
$931.00 K(+69.9%)
$61.00 K(-90.5%)
$931.00 K(+0.4%)
Sep 2013
-
$642.00 K(+2957.1%)
$926.90 K(+99.2%)
Jun 2013
-
$21.00 K(-89.9%)
$465.30 K(-12.1%)
Mar 2013
-
$207.00 K(+263.8%)
$529.50 K(-3.4%)
Dec 2012
$548.00 K(-47.9%)
$56.90 K(-68.5%)
$548.00 K(-25.2%)
Sep 2012
-
$180.40 K(+111.7%)
$732.20 K(+19.4%)
Jun 2012
-
$85.20 K(-62.2%)
$613.30 K(-46.3%)
Mar 2012
-
$225.50 K(-6.5%)
$1.14 M(+8.5%)
Dec 2011
$1.05 M(+2186.3%)
$241.10 K(+292.0%)
$1.05 M(+29.7%)
Sep 2011
-
$61.50 K(-90.0%)
$810.60 K(+8.2%)
Jun 2011
-
$613.30 K(+351.6%)
$749.10 K(+426.8%)
Mar 2011
-
$135.80 K(>+9900.0%)
$142.20 K(+2121.9%)
Dec 2010
$46.00 K
$0.00(0.0%)
$6400.00(0.0%)
Sep 2010
-
$0.00(-100.0%)
$6400.00(0.0%)
Jun 2010
-
$6400.00
$6400.00

FAQ

  • What is Sorrento Therapeutics annual capital expenditures?
  • What is the all time high annual CAPEX for Sorrento Therapeutics?
  • What is Sorrento Therapeutics annual CAPEX year-on-year change?
  • What is Sorrento Therapeutics quarterly capital expenditures?
  • What is the all time high quarterly CAPEX for Sorrento Therapeutics?
  • What is Sorrento Therapeutics quarterly CAPEX year-on-year change?
  • What is Sorrento Therapeutics TTM capital expenditures?
  • What is the all time high TTM CAPEX for Sorrento Therapeutics?
  • What is Sorrento Therapeutics TTM CAPEX year-on-year change?

What is Sorrento Therapeutics annual capital expenditures?

The current annual CAPEX of SRNE is $13.66 M

What is the all time high annual CAPEX for Sorrento Therapeutics?

Sorrento Therapeutics all-time high annual capital expenditures is $13.66 M

What is Sorrento Therapeutics annual CAPEX year-on-year change?

Over the past year, SRNE annual capital expenditures has changed by +$4.79 M (+53.95%)

What is Sorrento Therapeutics quarterly capital expenditures?

The current quarterly CAPEX of SRNE is $140.00 K

What is the all time high quarterly CAPEX for Sorrento Therapeutics?

Sorrento Therapeutics all-time high quarterly capital expenditures is $25.20 M

What is Sorrento Therapeutics quarterly CAPEX year-on-year change?

Over the past year, SRNE quarterly capital expenditures has changed by +$54.00 K (+62.79%)

What is Sorrento Therapeutics TTM capital expenditures?

The current TTM CAPEX of SRNE is $8.59 M

What is the all time high TTM CAPEX for Sorrento Therapeutics?

Sorrento Therapeutics all-time high TTM capital expenditures is $28.02 M

What is Sorrento Therapeutics TTM CAPEX year-on-year change?

Over the past year, SRNE TTM capital expenditures has changed by -$2.56 M (-23.00%)